Rapid Pathogen Screening
Manufacturing · Florida, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
7221 Delainey Ct, Sarasota, Florida, 342...Phone Number
(941) 556-1850Website
www.rpsdetectors.comRevenue
$5.4 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
1
1
1
About Rapid Pathogen Screening
RPS Diagnostics (RPS) is an emerging developer, manufacturer, and marketer of cost-effective point-of-care (POC) tests for systemic infectious disease and antibiotic stewardship. The company's innovative and patented FebriDx test is a rapid, disposable, in-office test that uses a finger stick blood sample to help identify a clinically significant immune response and differentiate bacterial from viral causes for fever in acute respiratory infection. With a 97% negative predictive value, FebriDx delivers results in 15 minutes and can be used to help triage infectious patients during the initial office visit, providing clinicians with actionable information that can be used to limit unnecessary antibiotics.Explore more
Rapid Pathogen Screening Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Rapid Pathogen Screening your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Congratulate Masked Content for being promoted to Masked Content at Rapid Pathogen Screening
Check if Rapid Pathogen Screening has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Website visits: Recent activity has been detected on your website
Funding: Get notified immidiatlly once Rapid Pathogen Screening has new funding data
Earning: See what the market has to say on Rapid Pathogen Screening recently announced quarterly report
Product Launch: Get notified when Rapid Pathogen Screening launches new products
Rapid Pathogen Screening, which may be a good buyer, showed buying intent in Masked Content Topic
Click to see if Rapid Pathogen Screening had a recent Job posting/layoffs
Check out if Rapid Pathogen Screening is spiking on competitors!
Recommended Actions
Introduce yourself to Masked Content, who has shown a strong intent to purchase lately
Find more new buyers
Compare Similar Companies to Rapid Pathogen Screening
Compare insights from companies similar to Rapid Pathogen Screening, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Rapid Pathogen Screening
$5.4M
11-50
Private
$34.6M
2004
DM
David MolleDirector, Eye Care Sales (US, East)
Company Profile Activity
Activity Insights
Rapid Pathogen Screening is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Rapid Pathogen Screening is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Rapid Pathogen Screening.
Rapid Pathogen Screening financials insights
Gather financial insights about Rapid Pathogen Screening, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2013
Unspecified
$6.3M
2014
Debt
$28M
2020
Debt
$350K
Rapid Pathogen Screening Tech Stack
A closer look at the technologies used by Rapid Pathogen Screening
See more technologies
Rapid Pathogen Screening News & Media
New Study Highlights the Utility of the FebriDx® Test for Rapid Triage and Identification of COVID-19
SARASOTA, Fla.--(BUSINESS WIRE)-- #COVID19--A newly published UK study highlights the utility of the FebriDx test for the rapid triage and identification of symptomatic COVID-19 patients.FebriDx® Test Featured in UK National Institute for Health and Care Excellence (NICE) Medtech Innovation Briefing (MIB)
SARASOTA, Fla.--(BUSINESS WIRE)-- #COVID19--Lumos today announced its rapid point-of-care FebriDx test was featured in United Kingdom NICE MIB guidance for the COVID-19 pandemic response.FebriDx® Receives Updated CE Mark to Allow Incorporation of All-in-One Test Format
RPS Diagnostics, Inc. today announced an updated CE mark of its FebriDx® test, clearing the way for its immediate launch in the European Union and all countries recognizing the CE mark. (PRWeb October 31, 2018) Read the full story at https://www.prweb.com/releases/febridx_receives_updated_ce_mark_to_allow_incorporation_of_all_in_one_test_format/prweb15878578.htmFebriDx® Receives Updated CE Mark to Allow Incorporation of All-in-One Test Format
SARASOTA, Fla.--(BUSINESS WIRE)--RPS Diagnostics (RPS) today announced an updated CE mark of its FebriDx test, clearing the way for its immediate launch in the European Union.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Rapid Pathogen Screening
Sign Up For FreeTo access detailed company insights
RPS Diagnostics (RPS) is an emerging developer, manufacturer, and marketer of cost-effective point-of-care (POC) tests for systemic infectious disease and antibiotic stewardship. The company's innovative and patented FebriDx test is a rapid, disposable, in-office test that uses a finger stick blood sample to help identify a clinically significant i... Read More
